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Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the
7-valent vaccine (PCV7) as the leading pneumococcal vaccine used in children through
the private sector. Although, neither of the PCVs were used significantly in adults,
changes in adult invasive pneumococcal disease (IPD) were expected due to herd
protection. We characterized n = 1163 isolates recovered from IPD in adults in
2012–2014 with the goal of documenting possible changes in serotype prevalence and
antimicrobial resistance. Among the 54 different serotypes detected, the most frequent,
accounting for half of all IPD, were serotypes: 3 (14%), 8 (11%), 19A (7%), 22F (7%),
14 (6%), and 7F (5%). The proportion of IPD caused by PCV7 serotypes remained
stable during the study period (14%), but was smaller than in the previous period
(19% in 2009–2011, p = 0.003). The proportion of IPD caused by PCV13 serotypes
decreased from 51% in 2012 to 38% in 2014 (p < 0.001), mainly due to decreases
in serotypes 7F and 19A. However, PCV13 serotype 3 remained relatively stable and
the most frequent cause of adult IPD. Non-PCV13 serotypes continued the increase
initiated in the late post-PCV7 period, with serotypes 8 and 22F being the most important
emerging serotypes. Serotype 15A increased in 2012–2014 (0.7% to 3.5%, p = 0.011)
and was strongly associated with antimicrobial resistance. However, the decreases in
resistant isolates among serotypes 14 and 19A led to an overall decrease in penicillin
non-susceptibility (from 17 to 13%, p = 0.174) and erythromycin resistance (from 19 to
13%, p = 0.034). Introduction of PCV13 in the NIP for children, as well as its availability
for adults may further alter the serotypes causing IPD in adults in Portugal and lead to
changes in the proportion of resistant isolates.
Keywords: Streptococcus pneumoniae, conjugate vaccines, polysaccharide vaccine, antimicrobial resistance,
invasive disease, serotype
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INTRODUCTION
Two types of pneumococcal vaccines are licensed to prevent
invasive pneumococcal disease (IPD), both targeting a restricted
number of serotypes out of the 94 serotypes currently recognized
in Streptococcus pneumoniae: strictly polysaccharide based
vaccines and polysaccharide-protein conjugate based vaccines
(PCVs) (Ramirez, 2014). The first licensed pneumococcal
conjugate vaccine was the 7-valent pneumococcal conjugate
vaccine (PCV7), which targets serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F. PCV7 became available for children in the USA in
2000 and in Europe in 2001. Two additional conjugate vaccines
became available more recently: a 10-valent vaccine (PCV10),
which includes PCV7 serotypes and serotypes 1, 5, and 7F; and
a 13-valent vaccine (PCV13), which includes PCV10 serotypes
and serotypes 3, 6A, and 19A. PCVs proved to be highly effective
in reducing the number of IPD episodes caused by vaccine
serotypes (Pilishvili et al., 2010; Aguiar et al., 2014). Moreover, a
decrease in IPD caused by PCV serotypes was also noted in non-
vaccinated individuals (a phenomenon termed herd protection)
(Horácio et al., 2013; Moore et al., 2015). However, use of PCVs
was also accompanied by replacement of vaccine serotypes by
non-vaccine types (NVTs) as causes of IPD, both in vaccinated
children and in non-vaccinated adults. The overall impact of this
phenomenon varied greatly around the world (Pérez-Trallero
et al., 2009; Guevara et al., 2014; Harboe et al., 2014; Moore
et al., 2015; Waight et al., 2015). The switch to the higher valency
vaccines PCV10 and PCV13 also affected emerging serotypes.
For instance, serotypes 7F and 19A were reported as emerging in
IPD in the post-PCV7 period (Aguiar et al., 2010; Steens et al.,
2013; Guevara et al., 2014; Harboe et al., 2014; Waight et al.,
2015) but several studies have already shown that they decrease
following PCV13 use (Aguiar et al., 2014; Moore et al., 2015;
Waight et al., 2015). A 23-valent strictly polysaccharide vaccine
(PPV23) includes 12 of the serotypes found in PCV13 (except 6A)
and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F.
This vaccine has been used for two decades in older children and
adults and has proven efficacy in the prevention of IPD (Moberley
et al., 2013).
PCV7, PCV10 and PCV13 became available in Portugal in
late-2001, mid-2009 and in early-2010, respectively. However,
in contrast to many European countries, in Portugal PCV7 was
not included in the national immunization program (NIP) and
the uptake of PCV7 in children increased gradually over time,
reaching 75% in 2008 (Aguiar et al., 2008). PCV13 replaced
PCV7 since its availability and has been the most widely used
pneumococcal vaccine since then, with estimates of 63% coverage
in 2012 (Aguiar et al., 2014). PCV13 received an indication
for adults ≥50 years in 2012 and in 2013 its indication was
extended to all ages, but use of these vaccines in adults in Portugal
was believed to be low until 2014. PCV13 was introduced into
the NIP for children in 2015, being given free of charge to all
children born from January 2015 onwards, with a 2+1 schedule
(Direcção Geral de Saúde, 2015b). PPV23 is also available in
Portugal since 1996, but its uptake among adults is estimated to
be low (∼10%) (Horácio et al., 2012). Since 2015, guidelines from
the national health authorities recommend vaccinating adults in
particular risk groups with both PCV13 and PPV23 (Direcção
Geral de Saúde, 2015a). However, these groups will constitute a
minority of the overall population and there are no guidelines
recommending vaccinating adults more broadly with any of the
pneumococcal vaccines.
In spite of the gradual increase in PCV uptake in children
and the relatively modest coverage, we found significant changes
in serotype distribution and antimicrobial susceptibility of
pneumococci causing adult IPD that could be attributed at least
in part to herd protection. The proportion of adult IPD caused
by PCV13 serotypes was highest in 2008 (70%), but a gradual
decrease took place until 2011, when only 54% of the isolates
causing adult IPD expressed PCV13 serotypes (Horácio et al.,
2012, 2013). In the present study we continued monitoring
potential changes in serotype distribution and antimicrobial
susceptibility of isolates causing adult IPD after PCV13 received
an adult indication and before the introduction of PCV13 in the
NIP for children.
MATERIALS AND METHODS
Ethics Statement
Case reporting and isolate collection were considered to be
surveillance activities and were exempt from evaluation by the
Review Board of the Faculdade de Medicina of Universidade de
Lisboa. The data and isolates were de-identified so that these were
irretrievably unlinked to an identifiable person.
Bacterial Isolates
Invasive pneumococcal infections have been monitored in
Portugal since 1999 by the Portuguese Group for the Study
of Streptococcal Infections (Serrano et al., 2004). This is a
laboratory-based surveillance system, in which 31 microbiology
laboratories throughout Portugal are asked to identify all isolates
responsible for IPD and to send them to a central laboratory
for characterization. Although, the laboratories were contacted
periodically to submit the isolates to the central laboratory,
no audit was performed to ensure compliance, which may be
variable in this type of study. A case of IPD was defined by the
isolation of pneumococci from a normally sterile fluid, such as
blood, pleural fluid or cerebral spinal fluid (CSF). The isolates
included in the study were recovered from adult patients (≥18
years) with IPD between January 2012 and December 2014.
Only one isolate from each patient in each year was included
in the study. All isolates were identified as pneumococci by
colony morphology, hemolysis on blood agar plates, optochin
susceptibility and bile solubility.
Serotyping and Antimicrobial Susceptibility
Testing
Serotypes were determined by the standard capsular reaction
test using the chessboard system and specific sera (Sørensen,
1993) (Statens Serum Institut, Copenhagen, Denmark). Serotypes
were classified into vaccine serotypes, i.e., those included in
PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), in PCV10
(all PCV7 serotypes plus serotypes 1, 5, and 7F), in PCV13
(all PCV10 serotypes plus 3, 6A, and 19A) or in PPV23 (all
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PCV13 serotypes, except serotype 6A and serotypes 2, 8, 9N,
10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F) and non-vaccine
serotypes (NVT). Given the high frequency of spontaneous
switching between serotypes 15B and 15C we have opted to
group isolates with these serotypes into a single group. Due to
difficulties in phenotypically distinguishing isolates of serotype
25A and serogroup 38 these were also grouped together into the
25A/38.
Minimal inhibitory concentrations (MICs) for penicillin and
cefotaxime were determined using Etest strips (Biomérieux,
Marcy l’Étoile, France). In 2008, the CLSI changed the
recommended breakpoints used to interpret MIC values.
Unless otherwise stated we have used the CLSI-recommended
breakpoints prior to 2008 (Clinical and Laboratory Standards
Institute, 2007) as epidemiological breakpoints that allow
the comparison with previous studies. Isolates were
further characterized by determining their susceptibility
to erythromycin, clindamycin, vancomycin, linezolid,
tetracycline, levofloxacin, trimethroprim-sulfamethoxazole and
chloramphenicol by the Kirby-Bauer disk diffusion technique,
according to the CLSI recommendations and interpretative
criteria (Clinical and Laboratory Standards Institute, 2014).
Macrolide resistance phenotypes were identified using
a double disc test with erythromycin and clindamycin, as
previously described (Melo-Cristino et al., 2003). Simultaneous
resistance to erythromycin and clindamycin defines the
MLSB phenotype (resistance to macrolides, lincosamides and
streptogramin B) while non-susceptibility only to erythromycin
indicates theM phenotype.
Statistical Analysis
Simpson’s index of diversity (SID) and respective 95% confidence
intervals (CI95%) was used to measure the population diversity
(Carriço et al., 2006). Adjusted Wallace (AW) coefficients
were used to compare two sets of partitions (Severiano et al.,
2011). These indices were calculated using the online tool
available at http://www.comparingpartitions.info. Differences
were evaluated by the Fisher exact test and the Cochran-Armitage
test (CA) was used for trends with the false discovery rate (FDR)
correction for multiple testing (Benjamini and Hochberg, 1995).
A p < 0.05 was considered significant for all tests.
RESULTS
Isolate Collection
A total of 1163 isolates were collected from adults with invasive
pneumococcal disease between 2012 and 2014: 404 in 2012, 383
in 2013 and 376 in 2014. The majority were recovered from blood
(n = 1066, 91.7%) and the remaining from CSF (n = 59, 5.1%),
pleural fluid (n = 26, 2.2%), peritoneal fluid (n = 9, 0.8%) and
other normally sterile sites (n = 3, 0.3%).
Serotype Distribution
Between 2012 and 2014, a total of 54 different serotypes were
identified. The most frequent, which accounted for half of the
isolates were serotypes 3 (n = 161, 13.8%), 8 (n = 123,
10.6%), 19A (n = 84, 7.2%), 22F (n = 79, 6.8%), 14 (n =
73, 6.3%), and 7F (n = 61, 5.2%). Figures 1–3 represent the
number of isolates expressing serotypes included in PCVs, the
additional serotypes found in PPV23, and the number of isolates
expressing NVTs stratified by age group. Serotype diversity was
high (2012–2014 SID = 0.944, CI95%: 0.939–0.949). Although,
diversity was >0.93 in all the studied years, there was a small
but significant increase in serotype diversity between 2012 (SID
= 0.935, CI95%: 0.924–0.945) and 2013 (SID = 0.950, CI95%:
0.942–0.958) (p = 0.019).
Serotype distribution varied according to age group but
serotype diversity was not different in the three age groups
considered (18–49 years, SID = 0.948, CI95%: 0.938–0.958;
50–64 years, SID = 0.945, CI95%: 0.933–0.957; ≥65 years, SID
= 0.939, CI95%: 0.931–0.946). Only for serotype 1 were the
differences in age distribution statistically supported after FDR
correction with the proportion of serotype 1 decreasing with
age (accounting for 6.5, 2.6, and 0.6% of the isolates recovered
from patients aged 18–49 years, 50–64 years and ≥65 years,
respectively, CA p < 0.001). In contrast, the proportion of IPD
caused by the group of additional serotypes found only in PCV13
(3, 6A, and 19A) increases with age (15.2% in 18–49 years, 19.9%
in 50–64 years and 24.7% in≥65 years, CA p = 0.002, significant
after FDR).
When considering serotypes presenting three or more CSF
isolates, we found a positive association with CSF for serotypes
19F (p = 0.006) and 23B (p = 0.005), both significant after FDR
correction (Table S1). No significant associations with serotype
were found for isolates recovered from pleural fluid.
Figure 4 shows the proportion of potentially vaccine
preventable IPD during the study period and, for comparison
purposes, also from 2008 to 2011 since important changes in
serotype distribution initiated in this period (Horácio et al.,
2013). Considering the current study period only (2012–2014),
the overall proportion of IPD caused by PCV7 serotypes
remained stable, while there was a decrease in the proportion of
IPD caused by the additional serotypes found in both PCV10
and PCV13 (serotypes 1, 5, 7F; from 11.1 to 4.8%, p = 0.001,
significant after FDR) and in PCV13 only (serotypes 3, 6A, and
19A; from 26.5 to 19.9%, p = 0.024, significant after FDR).
This resulted in the overall decrease in the proportion of IPD
caused by PCV13 serotypes from 51.2% in 2012 to 38.0% in
2014 (p < 0.001, significant after FDR). The proportion of IPD
caused by PPV23 serotypes and NVTs did not suffer significant
changes during the study period (Figure 4). However, the
proportion of IPD caused by the additional serotypes found
only in PPV23 (PPV23 add) significantly increased, from 27.2
to 38.0% (p = 0.001, significant after FDR). When considering
the evolution of potentially vaccine preventable IPD in the entire
period from 2008 to 2014, there was a decrease in the overall
proportion of IPD caused by PCV13 serotypes, although this was
temporarily interrupted in 2012, mainly due to a slight increase
of serotype 3 (see below).
Table 1 shows the evolution of individual serotypes causing
adult IPD from 2008 to 2014. When looking for trends in
the proportion of individual serotypes during the current
study period (2012–2014), the only significant change that was
supported after FDR correction was the decrease in serotype
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FIGURE 1 | Serotypes of isolates causing invasive pneumococcal disease in adult patients (≥18 years) in Portugal, 2012–2014. The number of isolates
expressing each serotype in each of the age groups considered is indicated. Isolates recovered from patients 18–49 years are indicated by black triangles, from
patients 50–64 years by open squares, and from patients ≥65 years by open circles. Isolates presenting both erythromycin resistance and penicillin non-susceptibility
(EPNSP) are represented by black bars. Penicillin non-susceptible isolates (PNSP) are indicated by dark hatched bars. Erythromycin resistant pneumococci (ERP) are
indicated by light hatched bars. Isolates susceptible to both penicillin and erythromycin are represented by white bars. The serotypes included in the seven-valent
conjugate vaccine (PCV7) and in the 13-valent conjugate vaccine (PCV13) are indicated by the arrows. NVT, non-vaccine serotypes; PPV23, 23-valent polysaccharide
vaccine.
7F (from 8.2% in 2012 to 4.7% in 2013 and 2.7% in 2014, CA
p < 0.001). No significant changes in the proportion of
individual serotypes were detected during the study period when
stratifying by age group (data not shown).
When considering together data from 2008 to 2014 there were
changes (significant after FDR) in the proportion of individual
serotypes. There were decreases in the proportion of IPD caused
by serotypes: 1 (from 13.4 to 1.9%, CA p < 0.001), 5 (from 2.9 to
0.3%, CA p < 0.001), 9V (from 3.4 to 0.3%, CA p < 0.001) and
19A (from 11.7 to 5.6%, CA p = 0.005). In contrast, there were
increases in the proportion of IPD caused by PPV23 serotypes: 8
(from 3.7 to 12.2%, CA p < 0.001), 22F (from 2.4 to 8.2%, CA
p < 0.001) and 20 (from 1.0 to 3.7%, CA p = 0.001); and an
increase of the NVT 15A (from 1.0 to 3.5%, CA p = 0.002). Even
though these changes were statistically supported when analyzing
data from 2008 to 2014, in the case of serotypes 19A and 15A,
the more disparate values were only detected from 2013 onwards,
while for serotype 20, this occurred from 2012 onwards.
Table 2 shows the evolution of IPD serotypes during the study
period (2012–2014) according to vaccine serotypes and stratified
by age group. Recapitulating what was seen when considering
all age groups together (Figure 4), a decrease in the overall
proportion of IPD caused by PCV13 serotypes was detected in
the three age groups considered; however, only for individuals
≥65 years was this statistically supported (Table 2). Moreover,
only for this age group was the decrease in the additional
serotypes found in both PCV10 and PCV13 (serotypes 1, 5 and
7F) statistically supported after FDR correction (Table 2). When
analyzing the evolution of each serotype from 2008 to 2014
stratifying by age group, only serotype 1 decreased in all age
groups considered (CA p < 0.001 for each, significant after FDR
correction), while the increase of serotype 8 was significant only
in the two older groups (≥50 years) (CA p < 0.001 for both,
significant after FDR correction), and the changes in serotypes
5, 7F, 19A, 20, and 22F were statistically supported only in
individuals ≥65 years (CA p < 0.001 for serotypes 5 and 7F,
CA p = 0.007 for serotype 19A, CA p = 0.003 for serotype
20 and CA p = 0.001 for serotype 22F, all significant after FDR
correction).
Antimicrobial Susceptibility
Resistance to the antimicrobials tested is summarized in Table 3.
A total of n = 179 isolates (15.4%) were classified as penicillin
non-susceptible pneumococci (PNSP): n = 160 (89.4%)
presenting low level resistance and n = 19 (10.6%), high level
resistance. Considering current CLSI breakpoints for penicillin,
n = 12/59 CSF isolates (20.3%) would have been considered
resistant and only n = 5/1104 non-CSF isolates (0.5%) would
have been considered intermediately resistant. A total of n =
198 isolates (17.0%) were classified as erythromycin resistant
pneumococci (ERP). Of these, n = 159 presented the MLSB
phenotype, while the remaining (n = 39, 19.7%) presented theM
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FIGURE 2 | Isolates expressing serotypes present in PPV23 but not included in conjugate vaccines causing invasive pneumococcal disease in adult
patients (≥18 years) in Portugal, 2012–2014. See legend of Figure 1. Out of the 11 serotypes present in PPV23 but absent from PCV13, serotype 2 was not
found in our collection.
phenotype. Isolates simultaneously non-susceptible to penicillin
and erythromycin (EPNSP) accounted for 10.4% of the collection
(n = 121).
Antimicrobial resistance did not change significantly
between age groups. In 2012–2014, there was a significant
decrease in antimicrobial resistance for several antimicrobials—
erythromycin resistance decreased from 18.8 to 13.0% (CA
p = 0.034), clindamycin resistance decreased from 16.1 to 10.4%
(CA p = 0.022) and tetracycline resistance decreased from 13.4
to 7.7% (CA p = 0.010). Although, not statistically supported,
there was also a decrease in penicillin non-susceptibility, from
16.8% in 2012 to 13.3% in 2014 (CA p = 0.174).
There was some correlation between serotype and
antimicrobial resistance (Figures 1–3). The AW for serotype
and PNSP was 0.569 (CI95%: 0.507–0.631) and the AW for
serotype and ERP was 0.527 (CI95%: 0.458–0.596). Serotypes
14 and 19A were the most frequent serotypes among PNSP and
ERP. Serotype 14 accounted for 35.2% of PNSP and 22.2% of
ERP while serotype 19A occurred in 21.2% of PNSP and 21.2%
of ERP. Taken together, PCV7 serotypes accounted for 48.6%
of PNSP, 37.9% of ERP and 40.5% of EPNSP. Considering the
PCV13 serotypes, these constituted 71.5, 61.1, and 67.8% of
PNSP, ERP and EPNSP, respectively. The additional serotypes
found in PPV23 but not in PCV13 accounted for only 2.8, 6.6,
and 1.7% of PNSP, ERP and EPNSP, respectively. The proportion
of resistant isolates was higher among isolates expressing NVTs:
25.7, 32.3, and 30.6% of PNSP, ERP and EPNSP, respectively
(Figures 1–3). The most frequent NVTs among PNSP and ERP
were serotypes 6C and 15A, which together accounted for 19.0%
of PNSP and 18.2% of ERP (Figure 3).
DISCUSSION
The decrease in PCV13 serotypes observed previously (Horácio
et al., 2012, 2013) continued during the present study period
resulting in only 38.0% of the isolates collected in 2014
expressing PCV13 serotypes (Figure 4). However, different
serotypes underlie the changes in 2008–2011 and 2012–2014.
The timeframes of the decreases seen for serotypes 7F and
19A are consistent with a possible herd protection of childhood
vaccination with the most recently introduced PCVs. Similar
decreases in serotypes 7F and 19A as causes of adult IPD
followed the use of PCV13 in children in the USA (Moore
et al., 2015) and in several European countries (Steens et al.,
2013; Guevara et al., 2014; Harboe et al., 2014; Waight et al.,
2015). Decreases in the incidence of IPD caused by these two
serotypes were also documented among children in Portugal
(Aguiar et al., 2014). In Portugal the decrease in serotype 7F
preceded that of serotype 19A in adult IPD. This could have
been attributed to the use of PCV10 in children, since PCV10
includes serotype 7F but not serotype 19A. Moreover, this
vaccine was introduced in Portugal months earlier than PCV13.
However, in children, serotype 19A decreased as a cause of
IPD before an effect of PCV13 was expected and before any
decrease in serotype 7F (Aguiar et al., 2014). This points to
the importance of other factors besides vaccination in triggering
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FIGURE 3 | Isolates expressing serotypes not included in any pneumococcal vaccine causing invasive pneumococcal disease in adult patients (≥18
years) in Portugal, 2012–2014. See legend of Figure 1. NT, non-typable. Isolates expressing serotype 25A and 38 could not be distinguished phenotypically and
are represented together. Only serotypes including n > 3 isolates are discriminated.
FIGURE 4 | Proportion of isolates expressing serotypes included in pneumococcal vaccines causing invasive pneumococcal disease in adult patients
(≥18 years) in Portugal, 2008–2014. The data up to 2011 were presented previously (Horácio et al., 2012, 2013).
changes in serotype prevalence and suggest that the initial
changes seen in serotype 7F IPD in adults are the result of secular
trends.
In contrast to these serotypes, there was no overall reduction
of serotype 3. These results are concordant with other studies that
failed to show a consistent reduction of serotype 3 among adult
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TABLE 1 | Serotypes of the isolates responsible for invasive pneumococcal disease in adult patients (≥18 years), 2008–2014.
Serotype No. of isolates (%) CAa CA
Current study period
2008 2009 2010 2011 2012 2013 2014 2012–2014 2008–2014
PCV13
1 55 (13.4) 48 (10.7) 22 (5.4) 17 (4.1) 12 (3.0) 7 (1.8) 7 (1.9) 0.289 <0.001
3 51 (12.5) 53 (11.8) 59 (14.6) 48 (11.6) 66 (16.3) 45 (11.7) 50 (13.3) 0.209 0.613
4 10 (2.4) 12 (2.7) 17 (4.2) 14 (3.4) 6 (1.5) 8 (2.1) 9 (2.4) 0.361 0.352
5 12 (2.9) 9 (2.0) 4 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 0.211 <0.001
6A 6 (1.5) 8 (1.8) 2 (0.5) 1 (0.2) 2 (0.5) 1 (0.3) 4 (1.1) 0.315 0.062
6B 1 (0.2) 7 (1.6) 3 (0.7) 9 (2.2) 5 (1.2) 5 (1.3) 5 (1.3) 0.909 0.272
7F 48 (11.7) 48 (10.7) 35 (8.7) 43 (10.4) 33 (8.2) 18 (4.7) 10 (2.7) 0.001 <0.001
9V 14 (3.4) 7 (1.6) 8 (2.0) 5 (1.2) 4 (1.0) 4 (1.0) 1 (0.3) 0.255 <0.001
14 29 (7.1) 45 (10.0) 30 (7.4) 31 (7.5) 29 (7.2) 26 (6.8) 18 (4.8) 0.172 0.045
18C 0 (0) 6 (1.3) 1 (0.2) 1 (0.2) 1 (0.2) 4 (1.0) 2 (0.5) 0.588 0.675
19A 48 (11.7) 33 (7.4) 44 (10.9) 38 (9.2) 39 (9.7) 24 (6.3) 21 (5.6) 0.027 0.005
19F 7 (1.7) 13 (2.9) 8 (2.0) 5 (1.2) 9 (2.2) 12 (3.1) 6 (1.6) 0.576 0.956
23F 6 (1.5) 4 (0.9) 5 (1.2) 9 (2.2) 1 (0.2) 3 (0.8) 9 (2.4) 0.005 0.618
PPV23 add
8 15 (3.7) 19 (4.2) 27 (6.7) 33 (8.0) 34 (8.4) 43 (11.2) 46 (12.2) 0.081 <0.001
9N 10 (2.4) 12 (2.7) 13 (3.2) 11 (2.7) 8 (2.0) 13 (3.4) 18 (4.8) 0.030 0.122
10A 3 (0.7) 8 (1.8) 7 (1.7) 6 (1.5) 2 (0.5) 8 (2.1) 8 (2.1) 0.062 0.294
11A 7 (1.7) 13 (2.9) 10 (2.5) 16 (3.9) 16 (4.0) 18 (4.7) 15 (4.0) 0.974 0.012
12F 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – 0.334
15B/C 8 (2.0) 4 (0.9) 3 (0.7) 8 (1.9) 5 (1.2) 9 (2.3) 8 (2.1) 0.353 0.096
17F 3 (0.7) 2 (0.4) 4 (1.0) 4 (1.0) 5 (1.2) 2 (0.5) 2 (0.5) 0.255 0.981
20 4 (1.0) 8 (1.8) 5 (1.2) 7 (1.7) 14 (3.5) 11 (2.9) 14 (3.7) 0.851 0.001
22F 10 (2.4) 17 (3.8) 16 (4.0) 22 (5.3) 25 (6.2) 23 (6.0) 31 (8.2) 0.261 <0.001
33F 0 (0) 0 (0) 1 (0.2) 0 (0) 1 (0.2) 1 (0.3) 1 (0.3) 0.959 0.180
NVTb
6C 4 (1.0) 13 (2.9) 13 (3.2) 10 (2.4) 8 (2.0) 14 (3.7) 6 (1.6) 0.757 0.600
15A 4 (1.0) 5 (1.1) 5 (1.2) 5 (1.2) 3 (0.7) 11 (2.9) 13 (3.5) 0.011 0.002
23A 6 (1.5) 8 (1.8) 8 (2.0) 4 (1.0) 9 (2.2) 8 (2.1) 9 (2.4) 0.879 0.317
16F 3 (0.7) 8 (1.8) 3 (0.7) 7 (1.7) 13 (3.2) 3 (0.8) 7 (1.9) 0.161 0.233
24F 3 (0.7) 6 (1.3) 5 (1.2) 2 (0.5) 5 (1.2) 9 (2.3) 9 (2.4) 0.241 0.027
12B 10 (2.4) 5 (1.1) 3 (0.7) 11 (2.7) 6 (1.5) 8 (2.1) 4 (1.1) 0.649 0.700
35B 2 (0.5) 5 (1.1) 10 (2.5) 5 (1.2) 6 (1.5) 4 (1.0) 8 (2.1) 0.480 0.222
35F 2 (0.5) 3 (0.7) 2 (0.5) 3 (0.7) 7 (1.7) 4 (1.0) 2 (0.5) 0.110 0.350
23B 4 (1.0) 3 (0.7) 7 (1.7) 6 (1.5) 4 (1.0) 5 (1.3) 3 (0.8) 0.801 0.958
31 2 (0.5) 2 (0.4) 1 (0.2) 5 (1.2) 5 (1.2) 2 (0.5) 4 (1.6) 0.786 0.197
NT 0 (0) 3 (0.7) 4 (1.0) 3 (0.7) 1 (0.2) 3 (0.8) 6 (1.6) 0.042 0.060
33A 1 (0.2) 4 (0.9) 8 (2.0) 4 (1.0) 2 (0.5) 5 (1.3) 2 (0.5) 0.929 0.913
25A/38 2 (0.5) 3 (0.7) 0 (0) 2 (0.5) 3 (0.7) 3 (0.8) 2 (0.5) 0.726 0.583
29 0 (0) 0 (0) 0 (0) 0 (0) 4 (1.0) 2 (0.5) 2 (0.5) 0.433 0.009
34 2 (0.5) 0 (0) 0 (0) 8 (1.9) 3 (0.7) 1 (0.3) 4 (1.1) 0.605 0.138
7C 2 (0.5) 2 (0.4) 2 (0.5) 1 (0.2) 1 (0.2) 4 (1.0) 1 (0.3) 0.942 0.883
18A 6 (1.5) 0 (0) 1 (0.2) 2 (0.5) 0 (0) 3 (0.8) 0 (0) 0.959 0.080
21 3 (0.7) 0 (0) 0 (0) 4 (1.0) 0 (0) 0 (0) 0 (0) – 0.108
Othersc 8 (2.0) 1 (0.2) 8 (2.0) 3 (0.7) 7 (1.7) 9 (2.3) 8 (2.1) – –
Total 409 448 404 413 404 383 376 – –
aCA, Cochran Armitage test of trend. In bold are the serotypes with significant p-values (p < 0.05) after FDR correction.
bNVT, non-vaccine serotypes.
cOnly serotypes detected in ≥3 isolates in at least one year are shown; the remaining are represented in “Others.”
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TABLE 2 | Number of isolates responsible for invasive pneumococcal
disease in adult patients (≥18 years), according to vaccine serotype
groups and age groups, 2012–2014.
Serotype
groups
No. isolates (%) CAa
2012 2013 2014
18–49 years PCV7b 18 (21.4) 12 (15.0) 8 (11.9) 0.112
1, 5, and 7F 15 (17.9) 10 (12.5) 8 (11.9) 0.286
3, 6A, and 19A 12 (14.3) 12 (15.0) 11 (16.4) 0.719
PCV13c 45 (53.6) 34 (42.5) 27 (40.3) 0.094
PPV23 addd 26 (31.0) 29 (36.3) 24 (35.8) 0.511
NVTse 13 (15.5) 17 (21.3) 16 (23.9) 0.191
50–64 years PCV7b 7 (9.2) 14 (13.9) 15 (16.7) 0.164
1, 5, and 7F 10 (13.2) 6 (5.9) 4 (4.4) 0.037
3, 6A, and 19A 20 (26.3) 19 (18.8) 14 (15.6) 0.087
PCV13c 37 (48.7) 39 (38.6) 33 (36.7) 0.124
PPV23 addd 17 (22.4) 34 (33.7) 37 (41.1) 0.011
NVTse 22 (28.9) 28 (27.7) 20 (22.2) 0.316
≥65 years PCV7b 30 (12.3) 36 (17.8) 27 (12.3) 0.947
1, 5, and 7F 20 (8.2) 9 (4.5) 6 (2.7) 0.008
3, 6A, and 19A 75 (30.7) 39 (19.3) 50 (22.8) 0.042
PCV13c 125 (51.2) 84 (41.6) 83 (37.9) 0.004
PPV23 addd 67 (27.5) 65 (32.2) 82 (37.4) 0.022
NVTse 52 (21.3) 53 (26.2) 54 (24.7) 0.384
aCA, Cochran Armitage test of trend. In bold are the serotype groups with significant p-
values (p < 0.05) after FDR correction.
bPCV7, serotypes included in the 7-valent pneumococcal conjugate vaccine.
cPCV13, serotypes included in the 13-valent pneumococcal conjugate vaccine.
dPPV23 add, the additional 11 serotypes present in the 23-valent pneumococcal
polysaccharide vaccine but absent from the 13-valent pneumococcal conjugate vaccine.
eNVTs, serotypes not included in any of the currently available pneumococcal vaccines.
IPD after the use of PCV13 in children (Steens et al., 2013; Harboe
et al., 2014; Moore et al., 2015; Waight et al., 2015) and with a
study that demonstrated a low and non-significant effectiveness
of PCV13 against serotype 3 IPD in children (Andrews et al.,
2014).
The proposed higher efficacy of PCV13 against serotype 19F
(Dagan et al., 2013) cannot explain the decrease in proportion
of PCV7 serotypes, since serotype 19F was uncommon in our
collection and no significant decrease was seen between the two
periods (Table 1). The reduction of the overall proportion of IPD
caused by PCV7 serotypes was instead related with decreases
in serotypes 4, 9V and 14 (Table 1). Among these, serotype 4
exhibited the most significant decrease. Since the most significant
decrease of serotype 14 IPD was detected in 2014, it remains
uncertain if it will be sustained in the following years. Serotype
14 has been the most frequent PCV7 serotype causing adult
IPD in Portugal, both before and after PCV7 use in children.
This could be associated with particular characteristics of the
highly successful and resistant clone Spain14-ST156, to which this
serotype was found to be associated (Horácio et al., 2016). High
antimicrobial consumption in our country could also contribute
significantly to maintain resistant clones such as this one in
circulation.
TABLE 3 | Antimicrobial resistance of the isolates responsible for invasive
pneumococcal disease in adult patients (≥18 years) in Portugal,
2012–2014.
No. resistant isolates (%)
18–49 years (n = 231) 50–64 years (n = 267) ≥65 years (n = 665)
PEN 40 (17.3) 32 (12.0) 107 (16.1)
MIC90 0.38 0.125 0.25
MIC50 0.016 0.012 0.016
CTX 4 (1.7) 3 (1.1) 6 (0.9)
MIC90 0.25 0.19 0.25
MIC50 0.016 0.016 0.016
LEV 0 (0) 1 (0.4) 6 (0.9)
ERY 34 (14.7) 37 (13.9) 127 (19.1)
CLI 31 (13.4) 30 (11.2) 100 (15.0)
CHL 5 (2.2) 6 (2.2) 8 (1.2)
SXT 30 (13.0) 39 (14.6) 93 (14.0)
TET 23 (10.0) 21 (7.9) 79 (11.9)
PEN, penicillin; CTX, cefotaxime; LEV, levofloxacin; ERY, erythromycin; CLI, clindamycin;
CHL, chloramphenicol; SXT, trimethoprim/sulphamethoxazole; TET, tetracycline. All
isolates were susceptible to vancomycin and linezolid.
The non-PCV serotypes that increased the most since the
late-post PCV7 period were those found in PPV23, especially
serotypes 8, 22F, and 20 (ranked by frequency); but also the
non-PPV23 serotype 15A (Table 1). Serotypes 15A and 22F
were found in carriage in adults in Portugal (Almeida et al.,
2014), while serotypes 8 and 20 were not found in carriage
in adults and were shown to have a high invasive disease
potential (Sá-Leão et al., 2011). Serotype 8 was the second
most frequent cause of IPD during the current study period
and in 2013 and 2014 was the most frequent cause of IPD
among younger adults (18–49 years). Serotype 8 increased in
importance as a cause of IPD in other countries, being the most
frequent cause of IPD in patients aged >5 years in England
and Wales after the introduction of PCV13 (Waight et al.,
2015) and also important in adult IPD elsewhere (Guevara
et al., 2014; Regev-Yochay et al., 2015). Serotype 22F became
the second most frequent cause of IPD in adults aged ≥65
years in 2013 and 2014. In the USA, this serotype was the
most common cause of adult IPD in the post-PCV13 period
(Moore et al., 2015). An increase of serotype 22F after PCV13
use was also reported in Canada (Demczuk et al., 2013) and
in some European countries (Steens et al., 2013; Lepoutre
et al., 2015). Serotype 20 increased more modestly and only
among individuals aged ≥65 years. An increase of this serotype
was also noted in Canada, although mostly among individuals
aged 15–49 years (Demczuk et al., 2013). Taken together, these
observations indicate that, although there may be some regional
differences, there are serotypes that seem to be consistently
emerging in different geographic locations in the post-PCV13
period. These may reflect circulating serotypes in asymptomatic
carriers but also serotypes with an enhanced invasive disease
potential.
In 2014, the last year of the study, serotype 15A surpassed
serotype 19A and 14 to become the most frequent serotype
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among ERP and was the second most frequent serotype among
PNSP behind serotype 14. The overall decreases observed in
PNSP and ERPwere not only due to decreases in the total number
of isolates expressing serotypes 14 and 19A, which were not
compensated by the increase in serotype 15A (Table 1), but also
to an unexpected decrease in the proportion of resistant isolates
within serotypes 14 and 19A. While 72% of serotype 14 and 64%
of serotype 19A were ERP in 2012, only 44% of serotype 14 and
33% of serotype 19A were ERP in 2014 (p = 0.071 and p = 0.031,
respectively). Similarly, there was a decrease in the proportion of
PNSP among serotype 19A, from 59% in 2012 to 24% in 2014
(p = 0.014).
Our surveillance system is exclusively laboratory based and
lacks compliance audits, so our study was not designed to
estimate the incidence of adult IPD. However, we did note a
slight decrease in the number of isolates sent to us in 2013
and 2014 (Figure 4). This could reflect a net reduction of adult
IPD following PCV13 use in children, as reported by others
(Guevara et al., 2014; Harboe et al., 2014; Lepoutre et al., 2015;
Moore et al., 2015; Regev-Yochay et al., 2015) and seen with
IPD in children in Portugal (Aguiar et al., 2014). Alternatively,
this could reflect lower reporting by participating laboratories.
We also noted a marked decrease in the number of isolates
recovered from younger patients relative to either of the older age
groups when comparing 2009–2011 to 2012–2014 (p < 0.001)
(Figure 1) (Horácio et al., 2013). Even if the decrease in number
of isolates is attributed to lower reporting, we have no reason to
believe that this would affect preferentially a particular age group.
We also have no indication of changes in clinical practice (such
as blood culturing practices), which could influence these results.
We therefore believe that the most likely explanation is a true
reduction in incidence of IPD in 18–49 years old individuals,
in agreement with a study from the UK that found that this
group was the one where the decrease in IPD incidence was more
pronounced and followed more closely PCV13 use in children
(Waight et al., 2015).
As discussed above, our study was not designed to allow the
estimate of the incidence of IPD and it therefore does not evaluate
potential changes in incidence with time. Specifically, although
we include the majority of medical centers in Portugal our
surveillance is not comprehensive and we did not perform audits
to ensure that participating centers reported all cases, namely we
did not include cases for which no viable pneumococcal isolate
was received for characterization. However, the design based on
the reporting of all isolates causing IPD within the surveillance
network, the large number of isolates studied, the wide coverage
of the country by the network and the stable number of reporting
centers, guarantees that the data accurately represents IPD in
Portugal and can be used to evaluate changes in the relative
importance of the different serotypes.
In spite of relatively modest vaccine coverage (63% in 2012),
there were major changes in the serotype distribution of the
pneumococcal population responsible for adult IPD in Portugal
following the use of PCVs in children consistent with herd
protection. These changes have contributed also to significant
reductions in antimicrobial resistance. The recent inclusion of
PCV13 in the NIP for children in Portugal may have an even
greater impact on IPD in adults. This remarkable effect of PCVs
in protecting non-vaccinated individuals may question the need
of using PCV13 directly in vaccinating adults. Still, data from
2014 indicates that the overall proportion of adult IPD caused
by PCV13 serotypes remained significant (38%) and that isolates
expressing PPV23 serotypes accounted for 75% of all IPD. Taken
together this suggests a key role of vaccination in any effective
management strategy of IPD.
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